Back to search

Article

A Drug-Specific, Half-Life-Adjusted Framework for Classifying CNS-Active Systemic Therapy Exposure During and After Radiotherapy

2026-06-22

Abstract excerpt

Clinical oncology datasets often store systemic therapy as a regimen label with a start date and an end date. Those records are clinically recognizable but can be analytically incomplete when the research question concerns whether a patient was exposed to a concurrent CNS-active drug ( cCNS-aD ) or an adjuvant CNS-active drug ( aCNS-aD ) around radiotherapy. Contemporary CNS-oncology studies usually define CNS a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b2d7e1e0-f24f-5d74-a2a7-4800fc1c7388
DOI
10.64898/2026.06.11.26354463
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A Drug-Specific, Half-Life-Adjusted Framework for Classifying CNS-Active Systemic Therapy Exposure During and After RadiotherapyDOI 10.64898/2026.06.11.26354463
Protective effects of testosterone replacement therapy on brain tumor outcomes: the Mayo Clinic ExperienceSemantic proximity
Immunotherapy Time of Infusion Impacts Survival in Head and Neck Cancer: A Propensity Score Matched AnalysisSemantic proximity
Estimation of US Patients with Cancer who may Respond to Cytotoxic ChemotherapySemantic proximity
Optimizing the Cumulative Cisplatin Dose for Concurrent Chemoradiotherapy Beneficiaries Among Elderly Nasopharyngeal Carcinoma Patients: A Real World StudySemantic proximity
A Reproducible Health Informatics Pipeline for Simulating and Integrating Early-Phase Oncology Clinical, Biomarker, and Pharmacokinetic Data for Exploratory Decision-Support AnalyticsSemantic proximity
Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden.Semantic proximity
Does The Reformed Cancer Drug Fund Generate Evidence On Effectiveness? A Cross-sectional Analysis On Publicly Accessible DocumentationSemantic proximity
The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in ScotlandSemantic proximity
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.Semantic proximity
Mandibular dose-volume predicts time-to-osteoradionecrosis in an actuarial normal-tissue complication probability (NTCP) model: External validation of right-censored clinico-dosimetric and competing risk application across international multi-institutional observational cohorts and online graphical user interface clinical support tool assessmentSemantic proximity
Discontinuation Risk from Adverse Events: Immunotherapy Alone vs. Combined with Chemotherapy: A Systematic Review and Network Meta-analysisSemantic proximity
Prior Sponsor Oncology Accelerated-Approval Activity and Post-Approval Regulatory Outcomes: A Retrospective Cohort StudySemantic proximity
Select a neighboring publication to make it the new centre.